Catabasis – Underwritten Registered Offering
Washington, DC – October 7, 2016 – Cooley advised the underwriters on Catabasis Pharmaceuticals’ $11.5 million underwritten registered offering.
Cowen and Company acted as sole book-running manager for the offering.
Catabasis, which trades on The NASDAQ Global Market, is a clinical-stage biopharmaceutical company focused on the discovery and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted (SMART) linker technology platform. Catabasis's SMART linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease.
Cooley advised the underwriters on Catabasis’s $69 million initial public offering in 2015.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 900 lawyers across 12 offices in the United States, China and Europe.
Related contacts
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.